Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? [Yahoo! Finance]
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "mkt outperform" rating. They now have a $5.00 price target on the stock.
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T [Yahoo! Finance]